Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 useful for the treatment of diabetes, obesity and dyslipidemia

A compound represented by Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: A and B together represents (a) C1-4alkylene optionally substituted with 1-3 halo groups, and 1-2 Ra groups in Ra represents C1-3alkyl, OC1-3alkyl, C1-6 arC6-10alquileno or phenyl optionally substituted with 1-3 halo groups, or (b) C2-5alcanodiilo so that a ring 3 is formed - 6 members with the carbon atom to which they are attached, said ring optionally containing 1 double bond or 1-2 heteroatoms selected from O, S and N, optionally substituted said 3-6 membered ring with C1-4alkylene, oxo, ethylenedioxy or propylenedioxy, and being further optionally substituted with 1-4 groups selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-3 acyl, C1-3 acyloxy, C1-3 alkoxy, alquilC1-6OC (O) -, alkenyl C2-4, C2-4alkynyl, C1-3alkoxy C1-3alkyl, C1-3alkoxy C1-3 alkoxy, phenyl, CN, OH, D, NH2, NHRa and N (Ra) 2 l that Ra is as previously defined; each R1 represents H or is independently selected from the group consisting of: OH, halo, alquiloC1-10, C1-6alkoxy and C6-10aryl, said alquiloC1-10, C6-10aryl and the alkyl portion of C1-6alkoxy optionally substituted with 1-3 halo, OH, OC1-3alkyl, phenyl or naphthyl groups, said phenyl and naphthyl optionally substituted with 1-3 substituents independently selected from halo, OCH3, OCF3, CH3, CF3 and phenyl, wherein said phenyl it is optionally substituted with 1-3 halo groups, or two R1 groups taken together represent a alquiloC5-6 ring or aryl, which may be optionally substituted with 1-2 OH or Ra groups, wherein Ra is as defined above; R2 and R3 are taken together or separately; when taken together, R2 and R3 represent (a) a C3-8 alkanediyl forming a fused ring nonaromatic 5-10 membered optionally interrupted with 1-2 double bonds, and optionally interrupted by 1-2 heteroatoms selected from O , S and N; or (b) a fused 6-10 membered aromatic group of monocyclic or bicyclic group being alkanediyl and said monocyclic or bicyclic aromatic optionally substituted with 1-6 halo atoms, and 1-4 of OH, C1-3alkyl, OC1-3alkyl , C1-3 haloalkyl, C1-3 haloalkoxy, and phenyl, said phenyl optionally substituted with 1-4 groups independently selected from halo, C1-3alkyl, OC1-3alkyl being, and wherein said C1-3alkyl and the C1-3alkyl portion OC1-3alkyl optionally substituted with 1-3 halo groups; when taken separately, R2 is selected from the group consisting of: (a) alquiloC1-14 optionally substituted with 1-6 halo groups and 1-3 substituents selected from OH, OC1-3alkyl, and phenyl, said phenyl optionally substituted with 1-4 groups independently selected from halo, OCH3, OCF3, CH3 and CF3, and said C1-3alkyl portion of OC1-3alkyl being optionally substituted with 1-3 halo groups; (b) phenyl or pyridyl optionally substituted with 1 -3 halo, OH or Ra, with Ra as previously defined; (C) C2-10 alkenyl, optionally substituted with 1-3 substituents independently selected from halo, OH and OC1-3alkyl, said C1-3alkyl portion of OC1-3alkyl optionally substituted with 1-3 halo groups being; (D) CH2CO2H; (e) CH2CO2alquiloC1-6; (F) CH2C (O) NHRa wherein Ra is as previously defined; (G) NH2, NHRa and N (Ra) 2 wherein Ra is as previously defined; and R3 is selected from the group consisting of: alquiloC1-14, alqueniloC2-10, SalquiloC1-6, C6-10aryl, heterocyclyl and heteroaryl, said alkyl, alkenyl, aryl, heterocyclyl, heteroaryl and the alkyl portion being SalquiloC1-6 optionally substituted with (a) R; (B) 1-6 halo groups and (c) 1-3 groups selected from OH, NH2, NH C1-4alkyl, N (C1-4alkyl) 2, C1-4alkyl, OalquiloC1-4, CN, C1-4alkylS (O ) x- where x is 0, 1 or 2, C1-4alkylSO2NH-, H2NSO2-, C1-4alkylNHSO2- and (C1-4alkyl) 2NSO2-, said C1-4alkyl and the C1-4alkyl portions of said groups optionally substituted phenyl and 1-3 halo groups, and R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 groups selected from halo, C1-4alkyl, C1-4alkylS (O) x-, with x as previously defined, C1-4alkylSO2NH-, H2NSO2-, C1-4alkylNHSO2-, (C1-4alkyl) 2NSO2-, CN, OH, OC1-4alkyl, and said C1-4alkyl and the C1-4alkyl portions said groups being optionally substituted with 1-5 halo and 1 group selected from OH and OC1-3alkyl.